Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Positive clinical results for mitoxantrone in multiple sclerosis

April 23, 1997

Piracetam as an adjuvant to language therapy for aphasia

April 23, 1997

Novel 5-HT uptake inhibitors from Bristol-Myers Squibb

April 23, 1997

AutoImmune freezes development of Myloral

April 22, 1997

BASF selects dual D4/5-HT2 antagonist for clinical development

April 22, 1997

MS&D designs potent and selective dopamine D4 antagonist

April 21, 1997

New opioid analgesic from Glaxo Wellcome

April 21, 1997

U.K. approval for Edronax

April 21, 1997

Imitrex Nasal Spray introduced in Canada

April 21, 1997

Warner-Lambert describes new dopamine D4 antagonists

April 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...